When darapladib, the specific inhibitor of Lp-PLA2, was added to statin therapy in patients with known CHD, there was a reduction in inflammatory markers such as CRP and IL-6, indicating a synergistic effect in inflammation amelioration. Here, IL6 is linked to coronary artery disorder.